Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Xenon Pharmaceuticals (Nasdaq: XENE) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026. The company presentation is scheduled for 9:00–9:40am PT (12:00–12:40pm ET) and will be delivered by Ian Mortimer, President and CEO. A live audio webcast will be available on Xenon’s investor website and posted for replay after the event. Dates and times are subject to change.
Program highlights: Xenon described its lead molecule azetukalner as a Kv7 potassium channel opener in Phase 3 for epilepsy, major depressive disorder and bipolar depression, and noted early-stage Kv7 and NaV1.7 programs in Phase 1 for pain.
Positive
- None.
Negative
- None.
News Market Reaction – XENE
In the Jan 5 session, XENE declined 6.07%, reflecting a notable negative market reaction. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 05 | Clinical data update | Positive | +0.7% | Presented 48‑month azetukalner epilepsy OLE data showing durable seizure reductions. |
| Dec 04 | Inducement grants | Neutral | +0.7% | Reported equity inducement option grants to new non-officer employees. |
| Dec 03 | Investor webinar | Positive | +3.3% | Announced investor webinar to review new azetukalner epilepsy data and plans. |
| Nov 25 | Upcoming data | Positive | +4.5% | Flagged upcoming AES 2025 presentations with long-term azetukalner epilepsy results. |
| Nov 06 | Investor conferences | Neutral | -0.9% | Outlined participation in two November 2025 healthcare investor conferences. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and data-focused news for XENE has generally coincided with modest positive next-day price moves, while conference-related headlines have shown smaller or slightly negative reactions.
Over the past few months, Xenon has highlighted steady progress for lead asset azetukalner. In November–December 2025, the company announced new long-term epilepsy data at AES 2025, an investor webinar to review results, and additional poster presentations, each followed by modest positive price reactions of up to 4.49%. Routine items such as inducement grants and investor conference presentations showed smaller or slightly negative moves. Today’s J.P. Morgan conference appearance fits into this pattern of ongoing investor engagement and visibility rather than a discrete clinical inflection.
Key Terms
kv7 potassium channel opener medical
major depressive disorder medical
bipolar depression medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, British Columbia and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, CA from January 12-15, 2026.
Company Presentation Details:
| Date: | Monday, January 12, 2026 |
| Time: | 9:00-9:40am Pacific Time (12:00-12:40pm Eastern Time) |
| Webcast: | Webcast - 44th Annual J.P. Morgan Healthcare Conference |
| Presenter: | Ian Mortimer, President and Chief Executive Officer, Xenon Pharmaceuticals |
A live audio webcast of the company presentation will be available on the Investors section of Xenon's website and posted for replay following the event. The above-mentioned dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including Kv7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.
Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements are not based on historical fact, and include statements regarding the timing of and potential results from clinical studies; the potential efficacy, safety profile, future development plans in current and anticipated indications, addressable market, regulatory success and commercial potential of our and our partners’ product candidates; the efficacy of our clinical study designs; our ability to successfully develop and achieve milestones in our azetukalner and other pipeline and development programs, including the anticipated filing of INDs and NDAs; the timing and results of our interactions with regulators; our ability to successfully develop and obtain regulatory approval of azetukalner and our other product candidates; and anticipated timing of topline data readout from our clinical studies of azetukalner. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: clinical studies may not demonstrate safety and efficacy of any of our or our collaborators’ product candidates; promising results from pre-clinical development activities or early clinical study results may not be replicated in later clinical studies; our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations may be incorrect; our ongoing discovery and pre-clinical efforts may not yield additional product candidates; any of our or our collaborators’ product candidates, including azetukalner, may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; regulatory agencies may impose additional requirements or delay the initiation or completion of clinical studies; the impact of market, industry, and regulatory conditions on clinical study enrollment; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; the impact of unstable economic conditions in the general domestic and global economic markets; adverse conditions from geopolitical events; as well as the other risks identified in our filings with the U.S. Securities and Exchange Commission and the securities commissions in British Columbia, Alberta, and Ontario. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.
Contact:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
Media: media@xenon-pharma.com
Investors: investors@xenon-pharma.com
